Whitehawk Therapeutics, Inc. 8-K

What Happened

• On May 7, 2026, Whitehawk Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 by issuing a press release. The press release is attached to the company's Form 8-K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: Quarter ended March 31, 2026.
• Press release attached as Exhibit 99.1 and furnished with the 8-K.
• Legal note (Item 9.01): the furnished exhibit is not to be deemed “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other SEC filings.

Why It Matters

• This 8-K signals Whitehawk has released its latest quarterly earnings and other financial metrics (revenue, net income/loss, cash position, any guidance) via the attached press release. Retail investors should read Exhibit 99.1 for the specific numbers and management commentary, since the 8-K itself primarily reports that the release was issued and furnished.